MARK SKOUSEN: Open Payments
NPI 1013529155 · SNOWFLAKE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$829 in 36 payments from 9 companies in 2025. Trend: 2023 $165 · 2024 $202 · 2025 $829
Food & beverage: $717Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $307 |
| Neurocrine BioSciences, Inc. | 5 | $112 |
| Otsuka America Pharmaceutical, Inc. | 4 | $102 |
| E.R. Squibb & Sons, L.L.C. | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $69 |
| Alkermes, Inc. | 2 | $58 |
| GlaxoSmithKline, LLC. | 2 | $39 |
| Janssen Pharmaceuticals, Inc | 1 | $29 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
Products named: AUSTEDO XR, INGREZZA, ABILIFY MAINTENA, COBENFY, FANAPT, LYBALVI, TRELEGY ELLIPTA, INVEGA SUSTENNA.
Industry payments across AZ — which companies pay providers there.
